About Bone Biologics Corp
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.bonebiologics.com/
Frequently Asked Questions
What is the 52-week range for BBLG?
The 52-week high is $2.89 and the 52-week low is $0.428.
What is the P/E ratio for BBLG?
The P/E ratio data is currently unavailable.
What is the dividend yield for BBLG?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -57.85%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.48.
Analyst Recommendation Trends
Wall Street analyst consensus for BBLG over the last few months:
Latest BBLG News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers GlucoTrack (NASDAQ:GCTK) stock moved upwards by 90.6% to $3.87 during Wednesday's after-market session. The market value of their outstanding shares is at $1.7 million. Greenland Mines (NASDAQ:GRML) shares
These stocks are moving in today's pre-market session
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Aethlon Medical (NASDAQ:AEMD) shares increased by 382.5% to $6.9 during Thursday's pre-market session. The company's market cap stands at $1.0 million. Akanda (NASDAQ:AKAN) stock rose 15.07% to $3.13.
Bone Biologics Expands Trial Sites
Addition of three sites strengthens expectation to complete enrollment by year-end 2026BURLINGTON, MA, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) (“Bone Biologics” or the “Company”), a developer of orthobiologic products for spine fusion markets, today announced that six hospital sites in Australia are now under agreement to participate in its first-in-human pilot clinical trial of NB1, the Company’s rhNELL-1-based bone graft product for spinal fusion. Th
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-01-08 | Walsh Deina H | +8,335 | - | - |
| 2026-01-08 | Frelick Jeff | +16,668 | - | - |